8-K: Actuate Therapeutics Secures \$50 Million Stock Purchase Agreement with B. Riley Principal Capital II

Actuate Therapeutics enters into a \$50 million common stock purchase agreement with B. Riley Principal Capital II, providing the company with flexible access to capital.

Summary

• Actuate Therapeutics has entered into a Common Stock Purchase Agreement with B. Riley Principal Capital II, allowing the company to sell up to \$50 million of its common stock.
• Sales of common stock are at Actuate's discretion and subject to certain conditions, including the effectiveness of a registration statement.
• The agreement spans a 36-month period, during which Actuate can direct B. Riley to purchase shares through Market Open Purchases and Intraday Purchases.
• The purchase price will be based on the volume-weighted average price (VWAP) during specific valuation periods, less a 3.0% discount.
• Actuate plans to use any net proceeds from the stock sales for working capital and general corporate purposes.
• The company is limited to issuing 3,904,374 shares, representing 19.99% of outstanding shares, unless stockholder approval is obtained or the average price exceeds \$7.56 per share.
• B. Riley is prohibited from engaging in short sales or hedging transactions on Actuate's common stock during the agreement's term.
• Actuate will pay B. Riley a cash commitment fee of up to \$500,000, representing 1.0% of the total purchase commitment, withheld from purchase prices.
• The agreement can be terminated under certain conditions, including reaching the \$50 million purchase limit, delisting from Nasdaq, or bankruptcy proceedings.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The agreement provides Actuate with access to capital, but also carries the risk of dilution. The terms are fairly standard for this type of financing.

Positives

• The agreement provides Actuate Therapeutics with access to up to \$50 million in capital.
• Actuate retains control over the timing and amount of stock sales.
• The funds are intended for general corporate purposes, offering flexibility in their use.
• B. Riley's commitment to purchase shares can provide market confidence.
• The agreement prohibits B. Riley from short selling the company's stock.

Negatives

• The agreement includes a 3.0% discount to VWAP, potentially diluting existing shareholders.
• The issuance of new shares could dilute existing shareholders' equity.
• The company is initially limited to issuing 3,904,374 shares unless certain conditions are met.
• The company must pay B. Riley a cash commitment fee of up to \$500,000.

Risks

• Actual sales of shares depend on market conditions and Actuate's funding needs.
• The agreement's reliance on VWAP makes it subject to market volatility.
• The potential issuance of a large number of shares could dilute existing shareholders.
• Failure to meet Nasdaq's continued listing requirements could terminate the agreement.
• The company's financial condition raises substantial doubt as to its ability to continue as a going concern.

Future Outlook

The Company currently plans to use any net proceeds from sales of Common Stock to B. Riley Principal Capital II for working capital and general corporate purposes.

Industry Context

This type of financing agreement is common in the biotech industry, providing companies with flexible access to capital to fund research and development activities. The agreement allows Actuate to draw down funds as needed, avoiding immediate dilution.

Comparison to Industry Standards

• Similar agreements are often seen with small-cap biotech companies seeking funding for clinical trials and operations.
• Comparable companies that have utilized similar financing structures include [hypothetical company A] and [hypothetical company B].
• The 3% discount to VWAP is within the typical range for these types of agreements.
• The commitment fee of 1% is also standard for such arrangements.

Stakeholder Impact

• Shareholders may experience dilution if Actuate sells a significant number of shares.
• Employees may benefit from the increased financial stability provided by the agreement.
• Customers and suppliers may see continued operations due to the company's access to capital.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• Actuate Therapeutics needs to file a registration statement with the SEC.
• Actuate Therapeutics needs to obtain stockholder approval to issue shares of Common Stock in excess of the Exchange Cap in accordance with applicable Nasdaq rules.
• Actuate Therapeutics needs to monitor market conditions and determine the appropriate timing for stock sales.
• Actuate Therapeutics needs to comply with all applicable securities laws and regulations.

Key Dates

Keywords

Common Stock Purchase Agreement, B. Riley Principal Capital II, Actuate Therapeutics, Capital Raise, Share Issuance, VWAP, Registration Rights, Financing, Equity, Nasdaq